Protocol. It is concluded that Malaysia biosafety regulation system satisfies this international requirement. However, with regards to enforcement of this Act, it remains unanswered, as no precedent has been reported. Interestingly, non-compliance of some proviso in the Biosafety Act 2007 will result in criminal penalty, and its impacts on the research and development in the biotechnology industry, commercial investment from abroad and domestic markets, and international trading of LMOs as food and feed, remain to be seen.
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Introduction
Ever since the discovery of DNA double helix structure [1] which paves the way of modern biotechnology, this leads the direction for the creation of living modified organisms (LMOhereinafter) involving bacteria, plants, and animals [2] . With the availability of some essential enzymes viz restriction enzymes, ligase, fragments of DNA from any organisms can be 'cut' (restricted) and 'joined' (ligated) to create what is commonly known as recombinant DNA.
This recombinant DNA can then be introduced into the recipient (host), hence creating Genetic Modified Organisms (GMOhereinafter).
In the last few decades, DNA recombinant technology has shown great potential in biomedical, agriculture, food production, and system biology [3] [4] [5] [6] . DNA recombinant may be regarded as another wave of post-modern industrial revolution. It allows molecular biologists to create many GMO, from the routine to somewhat controversial. Modern biotechnology that relies on DNA recombinant technology has indeed raised some concern in relations to the GMO itself, the side effects of this technology on both human and environment well-being as a whole [7] [8] [9] [10] .
On one hand, modern biotechnology is of great potential, but in order to protect human and environment from possible adverse effects of this technology, there is a need for checks and balances. Consequently, the Convention on Biological Diversity (CBD hereinafter) has entered into force on 29 December 1993, and after several years of negotiations, the Cartagena Protocol on Biosafety [11] (CPB hereinafter) to the CBD was adopted in Montreal on 29 January 2000 at an extraordinary meeting of the Conference of the Parties. This Protocol is to address inter alia, biosafety issue. CPB formed the very basis of an international regulatory framework that allows application of modern biotechnology and yet keeping its adverse effects at a minimal level through proviso in this Protocol.
Malaysia, being a member of the CBD, as required by the CPB ( [11] , Art. 2, p. 1) hence fulfilled its obligation to implement legal and administrative measures on biosafety by enacting the Biosafety Act 2007 [12] remains to be seen how both of the provisoes will apply on the use of RNA as 'modern biotechnology'
Overview
This paper will focus mainly on Parts III, IV and V of the 2007 Act which broadly satisfies the objective as stipulated in Article 1 5 of the CPB.
To provide a brief overview, the 2007 Act can be divided into eight parts, viz:
Part I -mainly concerns nomenclature and definitions used in the 2007 Act Part II -concerns establishment of the National Biosafety Board
Part III -apply to release activities and import activities involving LMOs Part IV -apply on the export, contained use and import for contained use activity Part V -apply on the risk assessment and risk management reports and emergency response plan Part VI -concerns mainly on the enforcement and its enforcement personnel Part VII -concerns miscellaneous issues such as confidential business information, labelling and public disclosure.
It is submitted that Part III of the 2007 Act which apply to release and import activities involving LMOs, which is in essence in line with the proviso stipulated in Article 7 of the CPB 6 .
Article 7 stipulated the need of regulation on import of LMO for release activity 7 into the environment of the import country 8 .
With reference to Article 6 [11] concerning the advance informed agreement procedure
shall not apply to the transboundary movement of LMOs destined for contained use which is duly reflected in section 11 (2) [12] 9 but note that even for contained use of LMOs, one shall satisfy the requirement of notification to the National Biosafety Board, as stipulated in section 21 [12] regardless it is for importation or exportation 10 . Article 8, Para 2 [11] provides that the party of export shall ensure that there is a legal requirement for the accuracy of information provided by the exporter. The burden of providing the notification and all relevant is placed on the party of export, which is reflected in s23(1) [12] stipulates 'that any person who intends to export LMOs shall comply with the requirements of the importing country on the importation of LMOs…'.
Risk Assessment and Risk Management
Under the Article 15, Para 1 [11] , risk assessments should be science-based, and in accordance with Annex III of the Protocol by taking into account recognized risk assessment techniques. Such risk assessments and other available scientific evidence in order to identify and evaluate the possible adverse effects of LMOs on the conservation and sustainable use of biological diversity, taking also into account risks to human health. In contrast to this article, [12] stipulates that the risk assessment and risk management reports shall be in a form prescribed by the Minister and shall contain an assessment of the risk and adverse effect that such LMOs and products of such organisms will have or are likely to have on the human, plant and animal health, the environment and biological diversity. Note that s36(1)(a) is silence on the issue of risk assessment whether it should be science-based. In s6(5) [12] , it is expressly stated that all member of the Genetic Modification Advisory Committee (GMAC) shall consist of experts from various science-based and other relevant disciplines. Mischief interpretation of s6 (5) together with Article 15 showed that albeit the 2007 Act is silent on the issue of sciencebased risk assessment, but through the inception of science-based committee (i.e. GMAC), it is submitted that risk assessment is still science-based. that some products remain to be LMO itself and hence are still capable of replication, and therefore products of the LMO warrants risk assessment. The opposite view on exclusion of risk assessment on products of LMO or "and product thereof" is because it is out of the scope of the Protocol and therefore there is no mandate on this requirement. 
s36(1)(a)

Risk Assessment
Risk Management
Accordingly, in s61 [12], which I quote 'all LMOs, items containing LMOs and products of such organisms shall be clearly identified and labelled in a manner to be prescribed and the requirements for such identification and labelling shall be in addition to any other written law'.
As the Malaysia Food Act 1983 [15] has been recently been amended 27 requiring the need of labelling of LMOs, s61 should be sufficient to cover the labelling of LMOs that used as food. It seems that no labelling is required when labelling of LMOs is needed when it is used as feed (cf Article 18).
Socio-economic Considerations
Although the risk assessment and risk management of LMOs is solely based on precautionary principle, science-based and balanced approach per se as manifested by the CPB, but it is also expressly stated that social-economic concern can be taken into consideration and research and information exchange with indigenous and local communities on LMOs ( [11] , Art.
26)
28
. 2007 Act has taken into account the public involvement as s14(c) [12] which subject to s59 [12] , shall for purposes of public disclosure, invite public participation, in such manner as may be determined by the Director General, for their views on the application. Note that the NBD is required by law to consider, inter alia, public opinion prior to granting approval for release and import of LMOs 34 . Also, s60(1) [12] provides that 'the public may have access to such information relating to any application for approval, approval granted or notification, which has not been granted confidentiality under s59 (2) 
Conclusion
The results of this study show that while certain clauses and proviso in the Protocol are highly similar, and some proviso in the 2007 Act are broader in scope, and conversely, certain clauses of the Protocol are well reflected in the 2007 Act . It is submitted that in overall perspective, 2007 Act is consistent with the CPB. It is believed that while no biotechnological activity notably genetic modification is absolutely risk-free, and safety is a matter of relative concept rather than an absolute principle, but nonetheless, it is arguable that with the Act enacted, Malaysia will be more equipped with national regulatory and legal framework to monitor its biosafety and issues. However, with regards to enforcement of this Act that involve personnel from a spectrum of expertise and ministries, it remains unanswered how this Act can be effective to protect biological diversity in this natural resources-rich country. Interestingly, non compliance of come proviso in the 2007 Act will result in criminal penalty, and its impact on the research and development in biotechnology industry, commercial investment from abroad and domestic markets, and international trading of LMOs as food and feed, particularly, remain to be seen. Gene Technology Act 2000. 6 Subject to Articles 5 and 6, the advance informed agreement procedure in Articles 8 to 10 and 12 shall apply prior to the first intentional transboundary movement of living modified organisms for intentional introduction into the environment of the Party of import ( [11] , Art. 7, para 1). 7 Section 11(1) [12] expressly stated the need of approval for import and release activity of LMO.
8 Article 7, Para 2 [11] , and s11(2) [12] excludes regulation of contained use of LMO.
9 Notwithstanding sub-s (1), this Part shall not apply to the importation of living modified organisms intended for purposes of undertaking a contained use activity ( [12] , s11(2)). 10 Part IV shall apply to the exportation and contained use activities involving living modified organisms and importation of living modified organisms for purposes of undertaking a contained use activity ( [12] , s21). 11 Where such person is an individual, to a fine not exceeding two hundred and fifty thousand ringgit or to imprisonment for a term not exceeding five years or to both and, in the case of a continuing offence, to a further fine not exceeding ten thousand ringgit for each day during which the offence continues after conviction ( [12] , s12(2)(a)). [13] . 19 Any approved person who contravenes s36(3) [12] commits an offence and shall, on conviction, be liable-(a) where such person is an individual, to a fine not exceeding two hundred and fifty thousand ringgit or to imprisonment for a term not exceeding five years or to both and, in the case of a continuing offence, to a further fine not exceeding ten thousand ringgit for each day during which the offence continues after conviction; (b) where such person is a body corporate, to a fine not exceeding five hundred thousand ringgit and, in the case of a continuing offence, to a further fine not exceeding twenty thousand ringgit for each day during which the offence continues after conviction. 20 See note 13 above. 21 Section 37(2) [12] : Any approved person who fails to take the necessary measures in an emergency according to the emergency response plan commits an offence and shall, on conviction, be liable-(a) where such person is an individual, to a fine not exceeding two hundred and fifty thousand ringgit or to imprisonment for a term not exceeding five years or to both and, in the case of a continuing offence, to a further fine not exceeding ten thousand ringgit for each day during which the offence continues after conviction; (b) where such person is a body corporate, to a fine not exceeding five hundred thousand ringgit and, in the case of a continuing offence, to a further fine not exceeding twenty thousand ringgit for each day during which the offence continues after conviction. 22 Any notification arising from Para 1 above, should include: (a) Available relevant information on the estimated quantities and relevant characteristics and/or traits of the living modified organism; (b) Information on the circumstances and estimated date of the release, and on the use of the living modified organism in the originating Party; (c) Any available information about the possible adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, as well as available information about possible risk management measures; (d) Any other relevant information; and (e) A point of contact for further information. ( [11] , art. 17, para 3) 23 In order to avoid adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, each Party shall take necessary measures to require that living modified organisms that are subject to intentional transboundary movement within the scope of this Protocol are handled, packaged and transported under conditions of safety, taking into consideration relevant international rules and standards. ( [11] , Art. 18, para 1) 24 Must 'clearly identifies that they "may contain" living modified organisms and are not intended for intentional introduction into the environment' ( [11] , Art. 18, para 2(a)). 25 Must 'clearly identifies them as living modified organisms; and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the living modified organisms are consigned' ( [11] , Art. 18, para 2(b)). 26 Must 'clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter' ( [11] , Art. 18, para 2(c)).
27 Food (Amendment No. 2) Regulations 2010. Amendment was made to Regulations 2, 11 and 17. In Food (Amendment) Regulations 2010, s3A requires approval for sale of food obtained through modern biotechnology. Sections 4 and 5 require that the origin of food and food ingredients obtained from modern biotechnology must be stated as "gene derived from (common name of such animal), "gene derived from (origin) and if such food is displayed for retail sale other than in a package, any such information shall be displayed on or in connection with the display of the food. 28 The Parties, in reaching a decision on import under this Protocol or under its domestic measures implementing the Protocol, may take into account, consistent with their international obligations, socio-economic considerations arising from the impact of living modified organisms on the conservation and sustainable use of biological diversity, especially with regard to the value of biological diversity to indigenous and local communities ( [11] , Art. 26, para 1) 29 See note 28 above. 30 See note 28 above.
31 Section 5.4, Paras 2 and 3, [16] states that '…NCBP shall issue guidelines relating to the conduct of social, economic, ethical, cultural and other assessments, as appropriate, particularly prior to decisions to commercialize products of modern biotechnology…these assessments shall be conducted separately from risk assessment and in a transparent, participatory and rigorous manner.'
32 Sections 48-67 [17] set up a clear process that the Gene Technology Regulator must follow in preparing a risk assessment and risk management plan and in making a decision about whether or not to issue a license. 33 Article 23, Para 2 [11] .
